Effective TRAIL-based immunotherapy requires both plasmacytoid and CD8α dendritic cells

  title={Effective TRAIL-based immunotherapy requires both plasmacytoid and CD8α dendritic cells},
  author={Britnie R James and Erik L Brincks and Tamara Kucaba and Louis Boon and Thomas S Griffith},
  journal={Cancer Immunology, Immunotherapy},
It is now appreciated that there are distinct subsets of dendritic cells (DC) with specialized functions. Plasmacytoid DC (pDC) and CD8α DC can contribute to the priming, activation and function of antitumor CD8 T cells; however, their specific roles and necessity in stimulating antitumor immunity are not clearly understood. We examined the importance of pDC and CD8α DC during immunotherapy of an orthotopic model of metastatic renal cell carcinoma. Immunotherapy that utilizes a recombinant… CONTINUE READING
Recent Discussions
This paper has been referenced on Twitter 1 time over the past 90 days. VIEW TWEETS


Publications referenced by this paper.
Showing 1-10 of 60 references

Henry MD, griffith tS (2012) eradication of metastatic renal cell carcinoma after adenovirus-encoded tnF-related apoptosis-inducing ligand (traIl)/Cpg immunotherapy

  • norian la, Kresowik tP, +6 authors CJ Weydert
  • PloS One 7(2):e31085
  • 2012
Highly Influential
11 Excerpts

translat - ing traIlreceptor targeting agents to the clinic

  • MW denHollander, gietema Ja, +4 authors de Vries eg
  • Cancer lett
  • 2013

Similar Papers

Loading similar papers…